Assessment of malignancy and PSMA expression of uncertain bone foci in [18F]PSMA-1007 PET/CT for prostate cancer—a single-centre experience of PET-guided biopsies

[1]  M. Zwahlen,et al.  Comparing the clinical performance and cost efficacy of [68Ga]Ga-PSMA-11 and [18F]PSMA-1007 in the diagnosis of recurrent prostate cancer: a Markov chain decision analysis , 2021, European Journal of Nuclear Medicine and Molecular Imaging.

[2]  F. Borgna,et al.  Impact of the mouse model and molar amount of injected ligand on the tissue distribution profile of PSMA radioligands , 2021, European Journal of Nuclear Medicine and Molecular Imaging.

[3]  A. Afshar-Oromieh,et al.  Clinical performance of long axial field of view PET/CT: a head-to-head intra-individual comparison of the Biograph Vision Quadra with the Biograph Vision PET/CT , 2021, European Journal of Nuclear Medicine and Molecular Imaging.

[4]  A. Afshar-Oromieh,et al.  The influence of digital PET/CT on diagnostic certainty and interrater reliability in [68Ga]Ga-PSMA-11 PET/CT for recurrent prostate cancer , 2021, Nuklearmedizin.

[5]  I. Burger,et al.  Focal unspecific bone uptake on [18F]-PSMA-1007 PET: a multicenter retrospective evaluation of the distribution, frequency, and quantitative parameters of a potential pitfall in prostate cancer imaging , 2021, European Journal of Nuclear Medicine and Molecular Imaging.

[6]  M. Latter,et al.  Clinical insignificance of [18F]PSMA-1007 avid non-specific bone lesions: a retrospective evaluation , 2021, European Journal of Nuclear Medicine and Molecular Imaging.

[7]  A. Afshar-Oromieh,et al.  Comparing the diagnostic performance of radiotracers in recurrent prostate cancer: a systematic review and network meta-analysis , 2021, European Journal of Nuclear Medicine and Molecular Imaging.

[8]  E. Even-Sapir,et al.  The significance of equivocal bone findings in staging PSMA imaging in the preoperative setting: validation of the PSMA-RADS version 1.0 , 2021, EJNMMI Research.

[9]  T. Holland-Letz,et al.  Diagnostic Accuracy of 18F-PSMA-1007 PET/CT Imaging for Lymph Node Staging of Prostate Carcinoma in Primary and Biochemical Recurrence , 2020, The Journal of Nuclear Medicine.

[10]  Michael Y. Chen,et al.  Solitary rib lesions showing prostate‐specific membrane antigen (PSMA) uptake in pre‐treatment staging 68Ga‐PSMA‐11 positron emission tomography scans for men with prostate cancer: benign or malignant? , 2020 .

[11]  Takahiro Higuchi,et al.  18F-Labeled, PSMA-Targeted Radiotracers: Leveraging the Advantages of Radiofluorination for Prostate Cancer Molecular Imaging , 2020, Theranostics.

[12]  K. Rahbar,et al.  The role of additional late PSMA-ligand PET/CT in the differentiation between lymph node metastases and ganglia , 2019, European Journal of Nuclear Medicine and Molecular Imaging.

[13]  A. Afshar-Oromieh,et al.  Digital versus analogue PET in [68Ga]Ga-PSMA-11 PET/CT for recurrent prostate cancer: a matched-pair comparison , 2019, European Journal of Nuclear Medicine and Molecular Imaging.

[14]  J. Miśko,et al.  Diagnostic performance of 18F-PSMA-1007 PET/CT in biochemically relapsed patients with prostate cancer with PSA levels ≤ 2.0 ng/ml , 2019, Prostate Cancer and Prostatic Diseases.

[15]  A. Afshar-Oromieh,et al.  PSMA-negative prostate cancer and the continued value of choline-PET/CT , 2019, Nuklearmedizin.

[16]  P. Carroll,et al.  Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial. , 2019, JAMA oncology.

[17]  Daniela A. Ferraro,et al.  First Clinicopathologic Evidence of a Non–PSMA-Related Uptake Mechanism for 68Ga-PSMA-11 in Salivary Glands , 2019, The Journal of Nuclear Medicine.

[18]  Koen Van Laere,et al.  Fibrous dysplasia mimicking bone metastasis on 68GA-PSMA PET/MRI , 2017, European Journal of Nuclear Medicine and Molecular Imaging.

[19]  T. Holland-Letz,et al.  PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions , 2013, European Journal of Nuclear Medicine and Molecular Imaging.

[20]  Thomas Krause,et al.  PET/CT-guided biopsies of metabolically active bone lesions: applications and clinical impact , 2010, European Journal of Nuclear Medicine and Molecular Imaging.

[21]  J. Wiskirchen,et al.  PET-CT-guided interventions in the management of FDG-positive lesions in patients suffering from solid malignancies: initial experiences , 2009, European Radiology.

[22]  P. Carroll,et al.  Assessment of 68 Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer A Prospective Single-Arm Clinical Trial , 2019 .

[23]  A. Šimundić,et al.  [Diagnostic accuracy]. , 2006, Acta medica Croatica : casopis Hravatske akademije medicinskih znanosti.

[24]  K. Rahbar,et al.  Diagnostic performance of 18 F-PSMA-1007 PET/CT in patients with biochemical recurrent prostate cancer , 2022 .